11:27 AM
Jan 04, 2018
 |  BC Innovations  |  Translation in Brief

ArunA’s exosome entrance

Why ArunA decided to develop exosome therapeutics for stroke

Stem cell manufacturer ArunA Biomedical Inc. has announced a pivot into the exosome therapeutic space, as well as publication of the first data showing its neural stem cell-derived exosomes and other extracellular vesicles are effective in mouse models of stroke.

ArunA launched in 2003 to provide stem cells to the research community.

According to co-founder, CEO and CSO Steven Stice, the company’s move into therapeutics development was driven by opportunities it saw arising in the young but rapidly developing field of exosomes. He told BioCentury exosomes can overcome some of the challenges associated with cell therapies, such as delivery and immunogenicity.

“We can deliver these systemically and there is no immune reaction, so we believe we can have a chronic as well as acute treatment,” he said.

He said ArunA’s expertise in cell manufacturing and experience gained interacting with FDA via its customers should give it a leg up...

Read the full 729 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Innovations

Article Purchase

$100 USD
More Info >